Key facts
- Notable investors include Ben Franklin Technology Partners of Central and Northern Pennsylvania.
- Status: Privately Held (backing).
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Oral Biolife
- ·The full record, as it builds
Funding rounds
No funding rounds for Oral Biolife are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Oral Biolife
Developer of dental therapeutics designed for the treatment of periodontal disease. The company specializes in therapies for oral and bone-related conditions with a combination of antimicrobial and bone regeneration properties that prevent the recolonization of bacteria, enabling dental practitioners to manage bacterial growth and support tissue repair in individuals with gum disorders.
- Sector
- Healthcare
- HQ
- Bethlehem, PA, United States
- Founded
- 2022
- Employees
- 8
- Website
- oralbiolife.com/
- Ownership
- Privately Held (backing)
Oral Biolife doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Oral Biolife shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Oral Biolife in its N-PORT filings yet. We sweep new filings monthly.